30
CARDIOVASCULAR
hamburger
product photo

THE NEXT STEP IN BTK EFFICACY

XIENCE Prime BTK Everolimus Eluting Peripheral Stent System is clinically proven for primary stenting of focal lesions and is engineered for outstanding performance.1

 

1. Bosiers, M et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease; J Vascular Surgery 2012;55:390-399.

XIENCE PRIME BTK EVEROLIMUS ELUTING PERIPHERAL
STENT SYSTEM

Xience Prime BTK
Advancing BTK Efficacy

Clinically Proven

  • Excellent long-term patency (angiographic binary in-stent restenosis (>50% stenosis)) of 85.2% and 98.7% limb salvage at 1 year.1,2



Xience Prime BTK Pre-procedure
Pre-procedure2
Xience Prime BTK Post-procedure
Post-procedure2
Xience Prime BTK 12 Months Post-procedure
12 months post-procedure2

 

Xience Prime BTK EngineeringEngineered For Outstanding Performance

  • Leading MULTI-LINK stent design for exceptional acute performance, uncompromised radial force, and visibility3
  • Coating technology for reliable expansion and controlled Everolimus drug release
  • Innovative delivery system for excellent deliverability and confident deployment

 

1. M. Bosiers, DESTINY, VEITH 2010
2. M. Bosiers, LINC 2011
3. Tests and data on file at Abbott

Xience Prime BTK Ordering Information

AP2946452-WBO Rev. A

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

True
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.